Abbott and AstraZeneca are planning to Phase III trial a pill combining two drugs to target all three major blood lipids--LDL-C "bad" cholesterol, HDL-C "good" cholesterol, and triglycerides. Abbott's ABT-335 and AstraZeneca's Crestor will make up the combo drug. If the drug is successful in trials, the companies plan to market the drug by 2009. Programs combining drugs have become very popular as of late as they offer beleaguered drug developers a way to make a quick buck.
- see this release for more
Related Articles:
New combos of old drugs may be boon to biotech. Report
Drug combos not a sure thing. Report